Eclosion SA
VC Fund
Geneva, Switzerland
Eclosion SA is a VC fund in Geneva focused on Biotechnology and Pharmaceutical. Eclosion assists entrepreneurs with the necessary resources to bridge the gap between their laboratories and the stage where the start-up
- Total investments:
- 16
- Last investment:
- Lead investor:
- 56%
Last updated:
For AI agents: llms.txt
Industries Eclosion SA invests in
Stages Eclosion SA invests in
Countries Eclosion SA invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
| See all 9 contacts → | |||
Round size
- Seed
- $1.6M–$2.7M
- Series C
- $20M–$28M
Investment Focus
Industry
- Biotechnology 12 (75%)
- Pharmaceutical 9 (56%)
- Health Care 5 (31%)
- Medical 4 (25%)
- Life Science 4 (25%)
Stage
- Seed 11 (69%)
- Series C 1 (6%)
- Funding Round 1 (6%)
- Post-IPO Equity 1 (6%)
- Convertible Note 1 (6%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Benoît Dubois
Team Member
|
Team Member | Total investments: 0 | Find email | |
|
Emanuela Dose-Sarfatis
Team Member
|
Team Member | Total investments: 0 | Find email | |
|
Gerard Gandillon
Team Member
|
Team Member | Total investments: 0 | Find email | |
|
Markus G. Schriber
Team Member
|
Team Member | Total investments: 0 | Find email | |
|
Robin E. Offord
Team Member
|
Team Member | Total investments: 0 | Find email | |
| See all 9 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
MPC Therapeutics
|
MPC Therapeutics develops a novel class of compounds with application in Immunotherapy and Metabolic diseases | $220.1K / Convertible Note / Apr 01, 2019 | |
| KYLYS is an innovative Swiss company based in Geneva founded in March 2017. KYLYS provides people and patients with highly effective and safe products based on biomolecules. | Seed / Jan 01, 2018 | ||
| Genkyotex is dedicated to the development of innovative drugs which block enzymes that produce oxygen radicals. Such novel drugs will allow the treatment of oxygen-radical mediated acute and chronic diseases, with improved specificity, safety, and efficacy over existing antioxidants therapy, giving them a significant competitive advantage.Genkyotex targets its technology initially to the therapeutic areas of cardiovascular, metabolic and neurodegenerative diseases. | $19.7M / Post-IPO Equity / Jan 07, 2015 | ||
DermAbiotech
|
DermAbiotech develops innovative targeted therapies for acute T cell-mediated inflammatory diseases. | Seed / Jan 01, 2015 | |
| Chord Therapeutics is a clinical-stage pharmaceutical company developing drugs for patients with rare, life-threatening, and severely disabling diseases. The company is advancing its lead drug candidate CRD1 under orphan drug designation for the treatment of neuromyelitis optica spectrum disorders (NMOSD) and myasthenia gravis (MG).The companywas founded in 2014 and based in Geneva, Switzerland. | Seed / Jan 01, 2015 | ||
| ID-GENE provides fast, sensitive, and reliable genetic tests for environmental bioassessment and biomonitoring.They aim to empower environmental agencies, consultancies, and the industry through innovative tools for environmental impact assessment. The company works to foster scientific innovation in an entrepreneurial mindset to makeenvironmental genomics accessible and to improve the long-term management of environmental resources. | Seed / Jan 01, 2015 | ||
| Geneva Biotech Center responds to the growing trend of pharmaceutical companies outsourcing research and development capabilities and acquiring projects in more advanced stages.Consequently, the GBC operates as a pre-pharmaceutical company: collaborating with selected partners to develop promising and innovative molecules, to be licensed to apharmaceutical company for their commercialization. | Seed / Jan 01, 2014 | ||
| As a private non-for-profit organisation, they strive to uncover the potential of existing molecules to address severe therapeutic unmet needs in rare diseases, thus giving better chances to existing drug to reach these underserved patients. | Seed / Jan 01, 2014 | ||
| Calypso Biotech is an innovative biopharmaceutical company based in Geneva, Switzerland and founded in 2013 as a spin-off from Merck Serono, a global leader in auto-immune diseases and biologics. Calypso Biotech was initially financed through a 2.5 million euro seed-fund managed by MS Ventures.A highly experienced management team with strongexpertise in drug development and an extensive scientific and industry network manages Calypso Biotech. They operate as a nimble, semi-virtual organization in order to create substantial added value for their investors from a portfolio of unique proprietary antibody candidates. | $2.7M / Seed / Mar 05, 2013 | ||
| Octave Biotech Consulting provides strategy and business development assistance to pharmaceutical and biotech companies. The company assists with partnering strategies, presentations, due diligence, structuring and negotiating term sheets and legal agreements, M&A, financial modelling, non-dilutive financing for development projects, and anyother business tasks related to the drug development and partnering process. It also assists people with finding and applying for non-dilutive funding to expand cash runway.Octave Biotech Consulting was founded on 2010 and is headquartered in Genève, Switzerland. | Seed / Jan 01, 2013 | ||
| See all 16 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Featured in Investor Lists
Recommended lists
FAQ
What does Eclosion SA invest in?
Eclosion SA invests primarily in Biotechnology, Pharmaceutical and Health Care startups, most often at Seed and Series C stage. Most of the 16 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Eclosion SA's check size?
Eclosion SA typically joins rounds of $1.6M–$2.7M at Seed and $20M–$28M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Eclosion SA participates in.
How do I contact Eclosion SA?
Public channels for Eclosion SA include the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Eclosion SA?
The team at Eclosion SA includes Benoît Dubois (Team Member), Emanuela Dose-Sarfatis (Team Member) and Gerard Gandillon (Team Member), among 9 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
